Lymphoma
Conditions
Keywords
stage III grade 3 follicular lymphoma, stage III adult diffuse small cleaved cell lymphoma, stage III adult diffuse mixed cell lymphoma, stage III adult diffuse large cell lymphoma, stage III adult immunoblastic large cell lymphoma, stage III adult Burkitt lymphoma, stage IV grade 3 follicular lymphoma, stage IV adult diffuse small cleaved cell lymphoma, stage IV adult diffuse mixed cell lymphoma, stage IV adult diffuse large cell lymphoma, stage IV adult immunoblastic large cell lymphoma, stage IV adult Burkitt lymphoma, contiguous stage II grade 3 follicular lymphoma, contiguous stage II adult diffuse small cleaved cell lymphoma, contiguous stage II adult diffuse mixed cell lymphoma, contiguous stage II adult immunoblastic large cell lymphoma, contiguous stage II adult diffuse large cell lymphoma, contiguous stage II adult Burkitt lymphoma, noncontiguous stage II grade 3 follicular lymphoma, noncontiguous stage II adult diffuse small cleaved cell lymphoma, noncontiguous stage II adult diffuse mixed cell lymphoma, noncontiguous stage II adult immunoblastic large cell lymphoma, noncontiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II adult Burkitt lymphoma
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation and kill more cancer cells. It is not yet known whether chemoradiotherapy plus peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying chemoradiotherapy and peripheral stem cell transplantation to see how well they work compared to combination chemotherapy in treating patients with stage II, stage III, or stage IV non-Hodgkin's lymphoma.
Detailed description
OBJECTIVES: * Compare the overall survival and progression-free survival of patients with intermediate- or high-grade non-Hodgkin's lymphoma treated with high-dose chemoradiotherapy and autologous peripheral blood stem cell transplantation (APBSCT) vs conventional dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (or CHOP plus rituximab for CD20+ disease) with possible late APBSCT. * Compare the toxic effects of these regimens in this patient population. OUTLINE: This is a randomized study. Patients are stratified according to disease risk (intermediate-high vs high). Patients receive CHOP chemotherapy comprising cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Patients with CD20-positive disease also receive rituximab IV on day 1 (or day 0 during course 1 only). Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity. Within 35 days of completing the fifth course, patients with partial or complete response are randomized to one of two treatment arms. * Arm I: Patients receive CHOP (or CHOP plus rituximab \[CHOP-R\]) as above. Treatment repeats every 3 weeks for 3 additional courses. After completion of chemotherapy, patients are encouraged to undergo harvest of peripheral blood stem cells (PBSC) for possible use at time of relapse. After completion of 8 courses, patients receive no additional therapy until disease progression or biopsy-proven disease. * Arm II: Patients receive one additional course of CHOP/CHOP-R followed by filgrastim (G-CSF), sargramostim (GM-CSF), or other colony-stimulating factors used singly or in combination according to center preference. PBSC are harvested and selected for CD34+ cells. Patients under age 61 receive one of two preparative regimens: a total body irradiation (TBI)-based regimen comprising irradiation administered twice daily on days -8 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2 OR carmustine IV over 2 hours on days -6 to -4 and etoposide and cyclophosphamide as in the TBI-based regimen. Patients age 61 to 65 receive the augmented regimen comprising carmustine, etoposide, and cyclophosphamide as above. Patients receive involved field radiotherapy prior to the preparative regimen only if there is biopsy-proven residual bulk disease and at the discretion of the center. PBSC are reinfused 36-48 hours after completion of cyclophosphamide. If both bone marrow and PBSC are harvested, bone marrow is reinfused on day 0 and then PBSC are reinfused either the same day or the following day. Patients are followed every 6 months for 2 years and then annually thereafter. PROJECTED ACCRUAL: Approximately 360 patients (at least 135 per treatment arm) will be accrued for this study within 5 years.
Interventions
BIOLOGICALrituximab
375 mg/m2 IV every 21 days
DRUGCHOP regimen
DRUGcarmustine
DRUGcyclophosphamide
DRUGdoxorubicin hydrochloride
DRUGetoposide
DRUGprednisone
DRUGvincristine sulfate
PROCEDUREbone marrow ablation with stem cell support
PROCEDUREperipheral blood stem cell transplantation
RADIATIONradiation therapy
Sponsors
National Cancer Institute (NCI)
Cancer and Leukemia Group B
Eastern Cooperative Oncology Group
NCIC Clinical Trials Group
SWOG Cancer Research Network
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically proven intermediate- or high-grade non-Hodgkin's lymphoma * Ann Arbor classification of bulky stage II, III, or IV * Must be classified as high-intermediate or high-risk according to International Age Adjusted Index * Bidimensionally measurable disease * No lymphoblastic, transformed, or mantle cell lymphomas * No CNS involvement by lymphoma * CD20 status confirmed by immunocytochemistry or flow cytometry * Must have either bilateral or unilateral bone marrow aspiration and biopsy ≥ 42 days before first course of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy (or CHOP plus rituximab \[CHOP-R\] for CD20+ disease) OR within 42 days prior to registration if CHOP/CHOP-R therapy has not begun * Must have bilateral bone marrow aspiration and biopsy within 28 days of randomization * Bone marrow involvement with lymphoma is allowed, provided there is an improvement of at least 50% if used as an evaluable site of disease * No prior lymphoma, Hodgkin's lymphoma, myelodysplastic syndromes, or leukemia NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age: * 15 to 65 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * No nonlymphoma-related hepatic dysfunction Renal: * Creatinine no greater than 2 times ULN * Creatinine clearance at least 60 mL/min * No nonlymphoma-related renal dysfunction * No history of grade 3 hemorrhagic cystitis due to cyclophosphamide Cardiovascular: * No coronary artery disease, cardiomyopathy, congestive heart failure, or dysrhythmia requiring therapy * MUGA scan or 2-D echocardiogram required if patient's history is questionable * Ejection fraction normal Pulmonary: * DLCO or FEV\_1 at least 60% of predicted Other: * Not pregnant or nursing * Fertile patients must use effective contraception * HIV negative * No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix * No allergy to etoposide * No active bacterial, fungal, or viral infection PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior monoclonal antibody therapy for lymphoma except if included in a single course of CHOP/CHOP-R Chemotherapy: * No prior chemotherapy for lymphoma except for a single course of CHOP/CHOP-R\* NOTE: \*Prednisone or other corticosteroids not considered prior chemotherapy Endocrine therapy: * See Chemotherapy * Prior corticosteroids allowed Radiotherapy: * No prior radiotherapy for lymphoma * No prior thoracic radiotherapy or radiotherapy greater than 2,000 cGy to any other site Surgery: * Not specified
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year Overall Survival Rates | up to 2 years post registration | Percentage of participants surviving 2 years post registration |
| 2 Year Progression-free Survival | From registration until death | Percentage of participants without disease progression up to 2 years post-registration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Duration of treatment and follow up until death or 3 years post registration | Adverse Events (AEs) are reported by CTCAE Version 2.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. Higher grades indicate higher severity of adverse events. |
Countries
Canada, United States
Participant flow
Pre-assignment details
397 participants were registered, of whom 27 were ineligible. Of the 370 eligible participants, 117 were excluded from randomization and so only 253 underwent randomization.
Participants by arm
| Arm | Count |
|---|---|
| CHOP/CHOP-R x 3 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 8 cycles
rituximab: 375 mg/m2 IV every 21 days
CHOP regimen
cyclophosphamide
doxorubicin hydrochloride
prednisone
vincristine sulfate
bone marrow ablation with stem cell support | 128 |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 6 cycles followed by autologous stem cell transplant.
rituximab: 375 mg/m2 IV every 21 days
CHOP regimen
carmustine
cyclophosphamide
doxorubicin hydrochloride
etoposide
prednisone
vincristine sulfate
bone marrow ablation with stem cell support
peripheral blood stem cell transplantation
radiation therapy | 125 |
| Total | 253 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 5 | 0 |
| Overall Study | Death | 3 | 1 |
| Overall Study | Other- not protocol specified | 3 | 3 |
| Overall Study | Progression/relapse | 9 | 4 |
| Overall Study | Reason under review | 3 | 2 |
| Overall Study | Refusal unrelated to adverse events | 2 | 11 |
Baseline characteristics
| Characteristic | Total | CHOP/CHOP-R x 3 | CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant |
|---|---|---|---|
| Age, Continuous | 50.6 years | 51.3 years | 49.6 years |
| Age, Customized % >=60 years | 19 percentage of participants | 18 percentage of participants | 20 percentage of participants |
| Bone marrow involvement- Yes | 50 Participants | 31 Participants | 19 Participants |
| B Symptoms | 156 Participants | 81 Participants | 75 Participants |
| Elevated LDH | 210 Participants | 104 Participants | 106 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 6 Participants | 2 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 219 Participants | 113 Participants | 106 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 28 Participants | 13 Participants | 15 Participants |
| Extra nodal Sites >=2 | 60 Participants | 29 Participants | 31 Participants |
| Immunophenotyping B cell CHOP | 75 Participants | 40 Participants | 35 Participants |
| Immunophenotyping B cell CHOP-R | 151 Participants | 76 Participants | 75 Participants |
| International Prognostic Index: High | 88 Participants | 44 Participants | 44 Participants |
| Performance status >= 2 | 92 Participants | 44 Participants | 48 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 5 Participants | 3 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 13 Participants | 6 Participants | 7 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) White | 228 Participants | 119 Participants | 109 Participants |
| Sex: Female, Male Female | 105 Participants | 56 Participants | 49 Participants |
| Sex: Female, Male Male | 148 Participants | 72 Participants | 76 Participants |
| Stage Bulky II | 13 Participants | 9 Participants | 4 Participants |
| Stage III | 47 Participants | 3 Participants | 44 Participants |
| Stage IV | 156 Participants | 78 Participants | 78 Participants |
| WHO B Cell Histology Diffuse Large B-Cell,Not Otherwise Specified | 164 Participants | 78 Participants | 86 Participants |
| WHO B Cell Histology WHO B Cell Histology | 224 Participants | 114 Participants | 110 Participants |
| WHO T Cell Histology Peripheral T, Not otherwise Specified | 10 Participants | 4 Participants | 6 Participants |
| WHO T Cell Histology WHO T Cell Histology | 29 Participants | 14 Participants | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 51 / 128 | 39 / 125 |
| other Total, other adverse events | 108 / 123 | 106 / 113 |
| serious Total, serious adverse events | 4 / 123 | 4 / 113 |
Outcome results
Primary
2-year Overall Survival Rates
Percentage of participants surviving 2 years post registration
Time frame: up to 2 years post registration
Population: Eligible participants that were randomized to study arms.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CHOP/CHOP-R x 3 | 2-year Overall Survival Rates | 71.1 percentage of participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | 2-year Overall Survival Rates | 73.7 percentage of participants |
Primary
2 Year Progression-free Survival
Percentage of participants without disease progression up to 2 years post-registration.
Time frame: From registration until death
Population: Eligible participants that were randomized to study arms.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CHOP/CHOP-R x 3 | 2 Year Progression-free Survival | 55.4 percentage of participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | 2 Year Progression-free Survival | 69.1 percentage of participants |
Secondary
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Adverse Events (AEs) are reported by CTCAE Version 2.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. Higher grades indicate higher severity of adverse events.
Time frame: Duration of treatment and follow up until death or 3 years post registration
Population: Patients who received at least one dose of protocol treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dizziness/light headedness | 9 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Alopecia | 43 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Insomnia | 9 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dizziness/vertigo, NOS | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Invol. movement/restlessness | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Infection, unk ANC | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Joint,muscle,bone-other | 4 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Double vision | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Keratitis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anemia | 57 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | LVEF decrease/CHF | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Liver-other | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dry skin | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Local injection site reaction | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GI-other | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Lung-other | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Lymphopenia | 59 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dyspepsia/heartburn | 6 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Melena/ GI bleeding | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anorexia | 8 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Memory loss | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dyspnea | 17 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Menses changes | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Inner ear-hearing loss | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Metabolic-other | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dysuria | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Mouth dryness | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anxiety/agitation | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Muscle weakness (not neuro) | 4 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Ear-other | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Myalgia | 15 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Delusions | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Nail changes | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Earache | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Nausea | 31 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Apnea | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Neuro-other | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Edema | 9 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Neuropathic pain | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Leukopenia | 68 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Neutropenia/granulocytopenia | 60 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Endocrine-other | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | PRBC transfusion | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Arthralgia | 5 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pain-other | 15 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Epistaxis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Palpitations | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Partial thromboplast time inc | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GU-other | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pericar. effusion/pericarditis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Erectile impotence | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Personality/behavioral change | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Arthritis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Petechiae/purpura | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Eryth/rash/eruption/desq, NOS | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Phlebitis | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Esophagitis/dysphagia | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Confusion | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pleural effusions | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Eye-other | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pneumonitis/infiltrates | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Ataxia (incoordination) | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Proctitis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | FEV1 decrease | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Proteinuria | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Lymphedema | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Prothrombin time increase | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fatigue/malaise/lethargy | 47 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pruritus | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Bicarbonate decrease | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pulmonary edema | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Febrile neutropenia | 10 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pulmonary fibrosis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hot flashes | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-GI mucositis, NOS | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fever without neutropenia | 5 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-esophagitis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Bilirubin increase | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-focal dermatitis, NOS | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fever, NOS | 5 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-pain | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Myalgia/arthralgia, NOS | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-pharyngeal dysphagia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Flu-like symptoms-other | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rash/desquamation | 7 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Blurred vision | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rectal bleeding/hematochezia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Flushing | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rectal/anal fistula | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Depression | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rectal/perirectal pain | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Focal dermatitis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Renal failure | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Bone pain | 6 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Reportable adverse event, NOS | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GGT increase | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Respiratory infect w/ neutrop | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dehydration | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Respiratory infect w/o neutrop | 4 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GI Mucositis, NOS | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Respiratory infection, unk ANC | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Bruising | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rigors/chills | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pigmentation changes/yellowing | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | SGOT (AST) increase | 9 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GVHD | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | SGPT (ALT) increase | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | CO diffusion capacity decrease | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | SIADH | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Gastritis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Salivary gland changes | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyperkalemia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Second primary | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Gynecomastia | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sense of smell | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cardiac ischemia/infarction | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sensory neuropathy | 46 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hallucinations | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sinus bradycardia | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Platelet transfusion | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sinus tachycardia | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hand-foot skin reaction | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Skin-other | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cardiovascular-other | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Somnolence/consciousness loss | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Headache | 6 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Stomatitis/pharyngitis | 12 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Abdominal pain/cramping | 8 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Supraventricular arrhythmia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hematuria | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Surgery-wound infection | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Catheter related infection | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sweating | 9 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hemorrhage-other | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Syncope | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Erythema multiforme/blistering | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Syndrome-other | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hiccoughs | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Taste disturbance | 7 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyperglycemia | 4 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Thrombocytopenia | 15 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypermagnesemia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Thrombosis/embolism | 3 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Chest pain,not cardio or pleur | 4 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-diarrhea | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypernatremia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-granulocytopenia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Conjunctivitis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-leukopenia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypertension | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-pRBC transfusion | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Alkaline phosphatase increase | 9 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-plt transfusion | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyperuricemia | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-rash/desquamation | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Constipation/bowel obstruction | 14 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-stomatitis/pharyng | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypoalbuminemia | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-thrombocytopenia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypoglycemia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Tremor | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypocalcemia | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary electrolyte wasting | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cough | 15 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary frequency/urgency | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Allergic reaction | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary retention | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypomagnesemia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary tr infect w/ neutrop | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Creatinine increase | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary tr infect w/o neutrop | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyponatremia | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | VOD associated weight gain | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Colitis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vaginal bleeding | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypophosphatemia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vaginal dryness | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cushingoid appearance | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vaginitis | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypotension | 1 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vision,NOS | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Allergic rhinitis | 4 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Voice change/stridor/larynx | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypoxia | 0 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vomiting | 15 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Diarrhea without colostomy | 13 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Weakness (motor neuropathy) | 13 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Infection w/o 3-4 neutropenia | 4 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Weight gain | 7 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypokalemia | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Weight loss | 2 Participants |
| CHOP/CHOP-R x 3 | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Infection with 3-4 neutropenia | 6 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Weight loss | 11 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Colitis | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Confusion | 5 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cushingoid appearance | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dehydration | 7 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Delusions | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Eryth/rash/eruption/desq, NOS | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Erythema multiforme/blistering | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GI-other | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hiccoughs | 6 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hot flashes | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyperglycemia | 21 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyperkalemia | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypoglycemia | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Infection, unk ANC | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | LVEF decrease/CHF | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Leukopenia | 81 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Lung-other | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Lymphedema | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Myalgia/arthralgia, NOS | 4 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Palpitations | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pigmentation changes/yellowing | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Abdominal pain/cramping | 9 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Alkaline phosphatase increase | 15 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Allergic reaction | 8 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Allergic rhinitis | 5 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Alopecia | 36 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anemia | 89 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anorexia | 32 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Anxiety/agitation | 12 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Apnea | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Arthralgia | 15 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Arthritis | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Ataxia (incoordination) | 6 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Bicarbonate decrease | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Bilirubin increase | 6 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Blurred vision | 4 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Bone pain | 4 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Bruising | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | CO diffusion capacity decrease | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cardiac ischemia/infarction | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cardiovascular-other | 4 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Catheter related infection | 11 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Conjunctivitis | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Constipation/bowel obstruction | 24 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Cough | 32 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Creatinine increase | 7 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Depression | 12 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Diarrhea without colostomy | 49 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dizziness/light headedness | 8 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dizziness/vertigo, NOS | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Double vision | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dry skin | 4 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dyspepsia/heartburn | 10 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dyspnea | 26 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Dysuria | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Ear-other | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Earache | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Edema | 32 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Endocrine-other | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Epistaxis | 4 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Erectile impotence | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Esophagitis/dysphagia | 9 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Eye-other | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | FEV1 decrease | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fatigue/malaise/lethargy | 67 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Febrile neutropenia | 44 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fever without neutropenia | 17 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Fever, NOS | 5 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Flu-like symptoms-other | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Flushing | 18 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Focal dermatitis | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GGT increase | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GI Mucositis, NOS | 10 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GU-other | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | GVHD | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Gastritis | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Gynecomastia | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hallucinations | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hand-foot skin reaction | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Headache | 26 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hematuria | 4 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hemorrhage-other | 5 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypermagnesemia | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypernatremia | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypertension | 5 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyperuricemia | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypoalbuminemia | 10 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypocalcemia | 13 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypokalemia | 10 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypomagnesemia | 6 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hyponatremia | 9 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypophosphatemia | 9 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypotension | 15 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Hypoxia | 6 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Infection w/o 3-4 neutropenia | 13 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Infection with 3-4 neutropenia | 17 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Inner ear-hearing loss | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Insomnia | 15 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Invol. movement/restlessness | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Joint,muscle,bone-other | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Keratitis | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Liver-other | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Local injection site reaction | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Lymphopenia | 80 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Melena/ GI bleeding | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Memory loss | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Menses changes | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Metabolic-other | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Mouth dryness | 9 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Muscle weakness (not neuro) | 10 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Myalgia | 19 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Nail changes | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Nausea | 66 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Neuro-other | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Neuropathic pain | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Neutropenia/granulocytopenia | 89 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | PRBC transfusion | 32 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pain-other | 17 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Partial thromboplast time inc | 5 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pericar. effusion/pericarditis | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Personality/behavioral change | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Petechiae/purpura | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Phlebitis | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Platelet transfusion | 37 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pleural effusions | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pneumonitis/infiltrates | 10 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Proctitis | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Proteinuria | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Prothrombin time increase | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pruritus | 7 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pulmonary edema | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Pulmonary fibrosis | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-GI mucositis, NOS | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-esophagitis | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-focal dermatitis, NOS | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-pain | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | RT-pharyngeal dysphagia | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rash/desquamation | 35 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rectal bleeding/hematochezia | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rectal/anal fistula | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rectal/perirectal pain | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Renal failure | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Reportable adverse event, NOS | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Respiratory infect w/ neutrop | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Respiratory infect w/o neutrop | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Respiratory infection, unk ANC | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Rigors/chills | 15 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | SGOT (AST) increase | 15 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | SGPT (ALT) increase | 9 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | SIADH | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Salivary gland changes | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Second primary | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sense of smell | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sensory neuropathy | 40 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sinus bradycardia | 4 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sinus tachycardia | 12 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Skin-other | 6 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Somnolence/consciousness loss | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Stomatitis/pharyngitis | 57 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Supraventricular arrhythmia | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Surgery-wound infection | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Sweating | 11 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Syncope | 0 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Syndrome-other | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Taste disturbance | 16 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Thrombocytopenia | 61 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Thrombosis/embolism | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-diarrhea | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-granulocytopenia | 5 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-leukopenia | 11 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-pRBC transfusion | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-plt transfusion | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-rash/desquamation | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-stomatitis/pharyng | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Transplant-thrombocytopenia | 13 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Tremor | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary electrolyte wasting | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary frequency/urgency | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary retention | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary tr infect w/ neutrop | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Urinary tr infect w/o neutrop | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | VOD associated weight gain | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vaginal bleeding | 2 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vaginal dryness | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vaginitis | 3 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vision,NOS | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Voice change/stridor/larynx | 1 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Vomiting | 40 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Weakness (motor neuropathy) | 4 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Weight gain | 8 Participants |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | Chest pain,not cardio or pleur | 9 Participants |